Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for HTG Molecular Diagnostics's Debt-to-Equity or its related term are showing as below:
HTGMQ's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.31 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
HTG Molecular Diagnostics Debt-to-Equity Related Terms
HTG Molecular Diagnostics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HTGMQ vs ABMC, TMO, DHR: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HTG Molecular Diagnostics Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where HTG Molecular Diagnostics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HTG Molecular Diagnostics (HTGMQ) has a Debt-to-Equity of 8.38 as of Mar. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on HTG Molecular Diagnostics and its competitors.
Is HTG Molecular Diagnostics' Debt-to-Equity too high?
HTG Molecular Diagnostics' current Debt-to-Equity is 8.38. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. HTG Molecular Diagnostics' value of 8.38 is 2603.2% above this industry median. Overall, HTG Molecular Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HTG Molecular Diagnostics' Debt-to-Equity compare to ABMC and TMO?
HTG Molecular Diagnostics' Debt-to-Equity of 8.38 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Debt-to-Equity is 0.31. HTG Molecular Diagnostics' value of 8.38 is 2603.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HTG Molecular Diagnostics's current Debt-to-Equity of 8.38 is 2603.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on HTG Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HTG Molecular Diagnostics's current Debt-to-Equity is 8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HTG Molecular Diagnostics stock overvalued right now?
HTG Molecular Diagnostics (HTGMQ) has a current Debt-to-Equity of 8.38. The current Debt-to-Equity is 8.38 and 2603.2% above the Medical Diagnostics & Research industry median of 0.31. HTG Molecular Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For HTG Molecular Diagnostics (HTGMQ), the current Debt-to-Equity is 8.38 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.
12GF Score
Get the complete analysis for HTGMQ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HTGMQ has been successfully added to your 
